Genocea Biosciences (NASDAQ:GNCA) Given “Outperform” Rating at SVB Leerink

SVB Leerink restated their outperform rating on shares of Genocea Biosciences (NASDAQ:GNCA) in a report issued on Sunday, AnalystRatings.com reports. SVB Leerink currently has a $5.00 price objective on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Genocea Biosciences from a sell rating to a hold rating in a report on Wednesday, July 1st. Needham & Company LLC restated a buy rating and issued a $10.00 price target on shares of Genocea Biosciences in a research note on Tuesday, May 12th. Finally, HC Wainwright restated a buy rating and issued a $32.00 price target on shares of Genocea Biosciences in a research note on Tuesday, June 23rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of Buy and an average price target of $12.31.

GNCA stock opened at $2.13 on Friday. The company has a quick ratio of 1.98, a current ratio of 1.98 and a debt-to-equity ratio of 1.28. Genocea Biosciences has a 12 month low of $1.10 and a 12 month high of $3.94. The firm has a market cap of $59.15 million, a P/E ratio of -1.42 and a beta of 2.35. The company’s 50-day moving average price is $2.46 and its two-hundred day moving average price is $2.17.

Genocea Biosciences (NASDAQ:GNCA) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.11). Equities analysts predict that Genocea Biosciences will post -1.56 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of GNCA. Renaissance Technologies LLC boosted its stake in shares of Genocea Biosciences by 37.4% in the 4th quarter. Renaissance Technologies LLC now owns 279,511 shares of the biotechnology company’s stock valued at $579,000 after purchasing an additional 76,149 shares in the last quarter. Oxford Asset Management LLP acquired a new stake in Genocea Biosciences during the 4th quarter worth approximately $27,000. FNY Investment Advisers LLC boosted its position in Genocea Biosciences by 9.1% during the 1st quarter. FNY Investment Advisers LLC now owns 300,000 shares of the biotechnology company’s stock worth $516,000 after buying an additional 25,000 shares during the period. NEA Management Company LLC acquired a new stake in Genocea Biosciences during the 1st quarter worth approximately $12,428,000. Finally, Bank of New York Mellon Corp acquired a new stake in Genocea Biosciences during the 1st quarter worth approximately $35,000. Institutional investors own 50.27% of the company’s stock.

About Genocea Biosciences

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

See Also: Basic Economics

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.